Rodolphe Barrangou’s work focuses on the characterization of CRISPR-Cas systems and their applications in bacteria, especially for the study and development of probiotics, including for genotyping, phage resistance, screening, genome editing and antimicrobials. He spent nine years in R&D and M&A at Danisco and DuPont, and has been at NC State since 2013. For his CRISPR work, he received several international awards, notably the Canada Gairdner International Award, and he was elected to the National Academy of Sciences, the National Academy of Engineering, and the National Academy of Inventors. Dr. Barrangou earned a BS in biological sciences from Rene Descartes University, France; an MS in biological engineering from the University of Technology in Compiegne, France; an MS in food science from NC State; a PhD in genomics from NC State; and an MBA from the University of Wisconsin-Madison. He is also the former chairman of the Board of Caribou Biosciences; a co-founder of Intellia Therapeutics, Locus Biosciences, TreeCo, Ancilia Biosciences, and CRISPR Biotechnologies; an advisor to Inari Ag, Invaio, Provaxus, Felix Biotech, and the IGI; and the editor in chief of the CRISPR Journal.